Yuichi Saito1, MD; Henning Kelbæk2, MD; Bo Xu3, MD; Yasin Hussain1, MD; Richard Anderson4, MD; Volker Schächinger5, MD; Ming Zheng6, MD; William Wijns7, MD; Andreas Baumbach1,8, MD; Alexandra J. Lansky1,8, MD
1. Yale University School of Medicine, New Haven, CT, USA; 2. Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark; 3. Fu Wai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 4. Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom; 5. Medizinische Klinik I, Herz-Thorax Zentrum, Klinikum Fulda, Fulda, Germany; 6. Shanghai MicroPort Medical (Group) Co., Ltd., Shanghai, China; 7. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, and Saolta University Healthcare Group, Galway, Ireland; 8. Barts Heart Centre, London, and Queen Mary University of London, London, United Kingdom
New-generation drug-eluting stents (DES), including both biodegradable and durable polymer stents, are currently recommended as a default strategy in percutaneous coronary intervention (PCI). A meta-analysis of 16 contemporary randomised DES trials demonstrated similar safety and efficacy of biodegradable polymer DES with respect to stent-related coronary events up to a mean follow-up period of 26 months compared to current-generation durable polymer DES, suggesting no clinical benefit of biodegradable polymer at least at two-year follow-up1. The Firehawk® (Shanghai MicroPort® Medical (Group), Co., Ltd., Shanghai, China) is a thin-strut coronary stent with sirolimus and biodegradable polymer complex localised in abluminal grooves ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Coronary interventionsSTEMINSTEMIStable CADStents and scaffolds
Read next article
Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction